Valion Bio, Inc. (VBIO): Entry into a Material Definitive Agreement
Valion Bio, Inc. (VBIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Series B Closing Valion Bio, Inc., a Delaware corporation (the “Company”), and 3i, LP (“3i”) are party to that certain Securities Purchase Agreement, dated as of April 29, 2025 (as assigned and amended as of December 9, 2025,
How this was made
The 30-second read
Why it matters
The capital raise provides cash but introduces dilution; short‑term price reaction may be modest.
Market read
Primary disclosure of a financing transaction for a micro‑cap biotech; limited but immediate relevance to shareholders.
Timing
today
Background
SEC Form 8‑K filing by Valion Bio (VBIO) reporting a material definitive agreement for preferred stock and warrant issuances.
Ticker impact
Valion Bio disclosed issuance of Series B and Series C non‑voting convertible preferred shares and accompanying warrants, raising up to $8.4M and $75M respectively.
potential dilution pressure as the market prices in the additional equity and warrant exposure
The filing is the first public disclosure of the financing; investors will assess dilution and cash use.
Market effects
May signal continued financing activity in the biotech micro‑cap sector.
US micro‑cap biotech market could see modest price adjustments.
Limited to niche investors; no broad market effect.
Key entities
- companyValion Bio, Inc.
Biotech firm issuing preferred shares and warrants.
- investor3i, LP
Investor participating in the Series B financing.
